23
PRESENTADO POR: Dr: Dairo Rey Residente II año medicina interna Ruby Martinez Ramirez Jany Mazo Morales

Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

Embed Size (px)

Citation preview

Page 1: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

PRESENTADO POR:Dr: Dairo Rey Residente II año medicina internaRuby Martinez RamirezJany Mazo Morales

Page 2: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

(1) Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible

clinical implications. QJM 2011 Jan;104(1):13-26.

Page 3: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 4: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

(1) Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible

clinical implications. QJM 2011 Jan;104(1):13-26.

Page 5: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 6: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 7: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 8: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 9: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 10: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 11: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 12: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 13: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 14: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

CONCLUSIÓN: Los resultados obtenidos en estos estudios soportan la suposición que los agentes bloqueantes anti TNF alfa, son capaces de reducir la incidencia de eventos cardiovasculares, especialmente en aquellos pacientes con responden clínicamente a la terapia.

Page 15: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

OTROS DMARDS

Page 16: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 17: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

(1) Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible

clinical implications. QJM 2011 Jan;104(1):13-26.

Page 18: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 19: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

Las alteraciones cardiovasculares en pacientes con AR tienen mayor incidencia, por lo tanto la muerte cardiovascular en esta población es mayor en comparación con la población no afectada por AR. Los cambios morfológicos son evidentes, determinándose:

•Variaciones a nivel molecular •disfunción endotelial •rigidez arterial•Cambios en la morfología arterial

No solo los factores de riesgos comunes influyen en la aparición de enfermedades cardiovasculares sino que también la inflamación crónica contribuye con este proceso

Page 20: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

CONCLUSIONES• En la actualidad el uso de MTX y TNF parece

proporcionar una reducción de los eventos cardiovasculares.

• Drogas como la leflunomida, ciclosporina, AINES e inhibidores de la COX-2 pueden empeorar los eventos cardiovasculares

• La función del tratamiento con GC en AR activa aun queda por determinar, no hay estudios concluyentes, por lo tanto queda por determinar.

Page 21: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications

BIBLIOGRAFÍA• (1) Pieringer H, Pichler M. Cardiovascular morbidity and mortality in

patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 2011 Jan;104(1):13-26.

Page 22: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Page 23: Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications